

FORM PTO/SB/08A
(REV. 10-96)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Sheet 1 of 2

Complete if Known

Application Number:	10/751,371
Filing Date:	January 5, 2004
First Named Inventor:	Mandrea, Eugene
Group Art Unit	not yet assigned
Examiner Name	not yet assigned.
Attorney Docket Number:	921880-95109

A U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/LW/	A.1	6,147,086	11-14-2000	Brenman	
	A.2				
	A.3				
	A.4				
	A.5				
	A.6				
	A.7				
	A.8				
	A.9				
	A.10				
	A.11				
	A.12				
	A.13				
	A.14				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A.15					
	A.16					
	A.17					
	A.18					
	A.19					

EXAMINER


/Leonard Williams/ (06/18/2007)

DATE CONSIDERED

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Send to: Assistant Commissioner for Patents, Washington, D.C. 20231.

FORM PTO/SB/08A (REV. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
Substitute for form 1449A/PTO				Application Number	10/751,371
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Filing Date	January 5, 2004
				First Named Inventor	Mandrea, Eugene
				Group Art Unit	unknown
				Examiner Name	not yet assigned.
Sheet <u>2</u> of <u>2</u>				Attorney Docket Number	921880-95109

B OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LW/	A.1	Arrese <i>et al.</i> , (2001) Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. <i>J Cutan Pathol.</i> 28(3):131-4..	
/LW/	A.2	Bishop <i>et al.</i> , (2001) The immune response modifier resiquimod mimics CD40-induced B cell activation. <i>Cell Immunol.</i> 25;208(1):9-17.	q
/LW/	A.3	Dahl MV (2002) Imiquimod: a cytokine inducer. <i>J Am Acad Dermatol.</i> 47 (4 Suppl):S205-8.	
/LW/	A.4	Dockrell and, Kinghorn (2001) Imiquimod and resiquimod as novel immunomodulators. <i>J Antimicrob Chemother.</i> 48(6):751-5	
/LW/	A.5	Gibson SJ (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. <i>Cell Immunol.</i> 218(1-2):74-86.	
/LW/	A.6	Hemmi <i>et al.</i> , (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. <i>Nat Immunol.</i> 3(2):196-200	
/LW/	A.7	O'Mahony <i>et al.</i> , (2001) New patient-applied therapy for anogenital warts is rated favourably by patients. <i>Int J STD AIDS.</i> 12(9):565-70	
/LW/	A.8	Stanley MA. (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. <i>Clin Exp Dermatol.</i> 27(7):571-7.	
	A.9		
	A.10		
	A.11		
	A.12		
EXAMINER	/Leonard Williams/ (06/18/2007)		DATE CONSIDERED

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 Applicant's unique citation designation number (optional)¹. Applicant is to place a check mark here if English language Translation is attached.
 SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO-1449**

Sheet 1 of 1

Application No.: 10/751,371
Filing Date: January 5, 2004
First Named Inventor: Eugene Mandrea
Art Unit: 1615
Examiner Name: Unassigned
Attorney Docket Number: 2209 P 002

U.S. PATENT DOCUMENTS

Examiner Initial	Document No. Kind Code (if known)	Name of Patentee or Applicant	Publication Date (MM-DD-YYYY)
/LW/	US 6,361,769 B1	Tovey	03-26-2002
/LW/	US 6,569,435 B1	Punnonen et al.	05-27-2003
/LW/	US 6,576,757 B1	Punnonen et al.	06-10-2003

FOREIGN PATENT DOCUMENTS

Examiner Initial	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	T
	Office	Number	Kind			

OTHER PRIOR ART OR NON-PATENT LITERATURE DOCUMENTS

Examiner Initial	(including Author (in capital letters), Title of the article, Title of the item, Date, Pages, Volume-Issue number, Publisher, City and/or Country where published.)	T
/LW/	CLEJAN, Sanda, et al., "Immune Responses Induced by Intranasal Imiquimod and Implications for Therapeutics in Rhinovirus Infections," April 2, 2005, pp. 457-461, J. Cell. Mol. Med., Vol. 9, No. 2	Y
/LW/	GASPARI, Anthony A., et al., "Immunotherapy of Basal Cell Carcinoma: Evolving Approaches," October 2003, pp. 1027-1034, American Society for Dermatologic Surgery, Inc., Volume 29, No. 10, Blackwell Publishing, Inc.	Y

Examiner Signature: /Leonard Williams/ (06/18/2007) Date Considered: _____

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.